Saroglitazar

化学情報

生物活性

プロトコル(参考用のみ)

参考

製品コードS9674 バッチS967401

	Synonyms	Lipaglyn, ZYH1	Storage (From the date of receipt)	2 years 4°C liquid
	化学式	C₂₅H₂₉NO₄S
	分子量	439.57	CAS No.	495399-09-2
Solubility (25°C)*	体外


* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

細胞アッセイ	細胞株	HepG2 cells
	濃度	--
	反応時間	20-22 h
	実験の流れ	HepG2 cells are seeded in 12-well plates at a density of 400,000 cells/well in 1 mL of medium per well. Cells are transfected with PPRE3-TK-luc and 0.08 μg of the pCDNA expression vector containing the cDNA of PPARa or 0.08 μg of the pSG5 expression vector containing the cDNA of PPARc using Superfect. Cells are incubated at 37 ℃, 5% CO2: 95% O2 and after 3 h 1.0 mL of the medium containing Saroglitazar are added to the respective wells. After the incubation for 20–22 h at 37 ℃ under 5% CO2, cells are first washed with Phosphate Buffer Saline (pH 7.3- 7.4), lysed and supernatant collected for luciferase and bgalactosidase activity. The luciferase activity is determined using commercial firefly luciferase assay according to the suppliers’ instructions in white 96-well plate. The bgalactosidase activity is determined in ELISA reader at 415 nm.
動物実験	動物モデル	B6.BKS(D)-Lepr^db/J(db/db) mice
	投薬量	0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg
	投与方法	Oral gavage

Saroglitazar (Lipaglyn, ZYH1) is an agonist of peroxisome proliferator-activated receptor (PPAR) with EC50 of 0.65 pM and 3 nM for hPPARα and hPPARγ in HepG2 cells, respectively.

in vitro

Saroglitazar is a novel nonthiazolidinediones (TZD) and nonfibric acid derivative designed to act as dual regulator of lipids and glucose metabolism by activating peroxisome proliferator-activated receptors (PPAR). The EC50 values of Saroglitazar assessed in HepG2 cells using PPAR transactivation assay for hPPARa and hPPARc are 0.65 pmol/L and 3 nmol/L, respectively.^[1]

In db/db mice, 12-day treatment with Saroglitazar (0.01–3 mg/kg per day, orally) causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose. Significant reduction in serum TG (upto 90%) is also observed in Zucker fa/fa rats, Swiss albino mice, and in high fat -high cholesterol (HF-HC)-fed Golden Syrian hamsters. LDL cholesterol is significantly lowered in hApoB100/hCETP double transgenic mice and HF-HC diet fed Golden Syrian Hamsters. Hyperinsulinemic-Euglycemic clamp study in Zucker fa/fa rats demonstrates potent insulin-sensitizing activity. Saroglitazar also shows a significant decrease in SBP (22 mmHg) and increase (62.1%) in serum adiponectin levels in Zucker fa/fa rats. A 90-day repeated dose comparative study in Wistar rats and marmosets confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans.^[1]

[1] Mukul R Jain, et al. Pharmacol Res Perspect. 2015 Jun;3(3):e00136.

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。